secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2025-04-10T23:59:59+00:00
Accession:  0001171843-25-002149
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience receives Nasdaq bid-price deficiency; CFO Cote resigns effective May 12
--------------------------------------------------------------------------------

- Nasdaq notified HBIO on April 4, 2025 of non-compliance with $1.00 minimum bid price; 180-day cure through Oct 1, 2025.
- CFO Jennifer Cote resigns effective upon filing Q1 10-Q (due by May 12, 2025); resignation not due to any disagreement.
- Mark Frost appointed interim CFO and Treasurer effective on Cote's departure; base salary $320k, $50k bonus tied to full debt repayment.
- Frost receives 100k time-based RSUs vesting in one year, with pro-rata vesting if terminated without cause.
- If not cured, HBIO may transfer to Nasdaq Capital Market for second 180-day period or face delisting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184325002149/0001171843-25-002149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184325002149/f8k_041025.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer